Women who take the chemotherapy drug trastuzumab (Herceptin) for HER2-positive breast cancer can be at higher risk for heart failure and should have their hearts monitored during treatment, new research finds. The complication is not common, and in many cases, the benefits of the chemotherapy still outweigh the risks. But regular checks should be a priority.

Source: Medical News